The thiol group (SH) on glutathione's cysteine residue is the functional part that donates electrons during detoxification and antioxidant reactions
It's an investigational drug in Phase 3 clinical trials Expected availability: 2027-2028 after FDA approval, assuming Phase 3 trials complete successfully Current access options: Clinical trial enrollment (free), compounding pharmacies with prescription ($200-500/month), or research peptides ($150-500/month) By country: Not approved in US, UK, EU, Australia, or Canada
Quick Answer: Semaglutide is not contraindicated in ulcerative colitis, but its gastrointestinal side effects may complicate symptom monitoring and disease management
The weight loss achieved through this medication is often accompanied by better blood sugar control, lower blood pressure, and improved lipid levels
Results from an initial Phase III trial in December also did not meet expectations, which triggered a 19% decline in Novos share price
External resources SURPASS-2 trial: tirzepatide vs semaglutide (New England Journal of Medicine) SURMOUNT-1 trial: tirzepatide for obesity (New England Journal of Medicine) In case I do not see you, good afternoon, good evening, and good night
